Alectinib (Alecensa®) is a small molecule kinase inhibitor which has received FDA accelerated approval for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib treatment [43]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.